Health Economics›Melanoma›Adjuvant therapy

Adjuvant therapy

Melanoma · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ipilimumab monotherapy Variant #01	—	R 786 153	84d	—	—	4	R 3 144 612 PFS proxy	2
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~5.3 mo	~36.1 mo	~52	~R 14 921 674 PFS proxy · indirect	11
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	—	—	9	R 707 538 PFS proxy	2
Dabrafenib and Trametinib Variant #01	BRAF	R 52 791	28d	—	—	2	R 105 582 PFS proxy	1
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	—	—	52	R 992 271 PFS proxy	1
Vemurafenib monotherapy Variant #01	BRAF	R 13 464	28d	~7.2 mo	~15.5 mo	~2	~R 26 928 PFS proxy · indirect	4
CVD, IL-2, IFN alfa-2b - sequential biochemotherapy Variant #01 Partial	—	R 8 684	21d	—	118.8 mo	6	R 52 102 PFS proxy	1
Cisplatin and Temozolomide Variant #01	—	R 5 347	21d	—	—	~6	~R 32 080 indirect	—
Peginterferon alfa-2b monotherapy Variant #01	—	R 14	7d	—	—	~252	~R 1 273 indirect	—
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~4.6 mo	~34.1 mo	~2	—	10
Interferon alfa-2b monotherapy Variant #01 Partial	—	—	28d	~13.2 mo	—	~48	—	2
Interferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	~5.4 mo	~17.5 mo	~2	—	10
Placebo Partial	—	—	—	—	46.8 mo	—	—	1
Observation Partial	—	—	—	—	—	—	—	1
Placebo Partial	BRAF	—	—	—	46.8 mo	—	—	1

15 of 15 regimens shown